RSS
18 Jan 2022

Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Author: admintech | Filed under: Press Release

DUBLIN, Jan. 18, 2022 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology…

This entry was posted on Tuesday, January 18th, 2022 at 7:10 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»